Percutaneous closure of perivalvular leaks with Amplatzer® occluders: Feasibility, safety, and short-term results

Yaron Shapira*, Rafael Hirsch, Ran Kornowski, David Hasdai, Abid Assali, Mordehay Vaturi, Horst Sievert, Ralph Hein, Alexander Battler, Alex Sagie

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background and aim of the study: Perivalvular leak (PVL) may have significant hemodynamic and/or hematological consequences, and re-do surgery is associated with considerable mortality and morbidity. Herein are reviewed the short-term results of percutaneous closure of PVLs using the Amplatzer® occluder. Methods: Eleven patients (five males, six females; mean age 59.7 ± 7.3 years; range: 46-67 years) were referred for percutaneous closure of PVL using the Amplatzer occluder. Patients presented with congestive heart failure (n = 2), hemolysis (n = 1), or both (n = 8). The average number of previous heart operations was 2.4 ± 1.3 per patient; seven patients had undergone two or more operations. The procedure was performed under general anesthesia, with fluoroscopic and transesophageal echocardiographic guidance. Antegrade and retrograde approaches were used for the mitral and aortic leaks, respectively. Results: The PVLs were in the mitral position (n = 8), aortic position (n = 1), or both (n = 2). Device deployment was achieved in 11 (91.7%) of 12 attempted valves (10 patients, 90.9%). Failure to cross the leak with the wire occurred in one patient, and interruption of mitral leaflet movement occurred in two patients. Leakage was decreased in six patients (60%), but residual leak was observed at 10 of the 11 sites. Hemolysis was reduced in four patients, increased in four, and remained unchanged in two. An improved NYHA functional class of one grade was noted in five patients. One patient required a second operative session to seal a residual leak. Conclusion: Percutaneous closure of PVL using the Amplatzer occluder is feasible, but technically demanding. Although symptoms were improved, there was an inconsistent effect on hemolysis. At present, the Amplatzer occluder should be reserved for poor surgical candidates.

Original languageEnglish
Pages (from-to)305-313
Number of pages9
JournalJournal of Heart Valve Disease
Issue number3
StatePublished - May 2007


Dive into the research topics of 'Percutaneous closure of perivalvular leaks with Amplatzer® occluders: Feasibility, safety, and short-term results'. Together they form a unique fingerprint.

Cite this